Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, phase I dose finding study, followed by a phase II
expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a
projected enrolment of 33 patients with refractory solid tumors to determine the RP2D. In the
phase II portion, a total of 30 patients with advanced/metastatic TNBC will be enrolled.